CN101977589B - Chitosan gel for dermatological use, production method therefor and use of same - Google Patents
Chitosan gel for dermatological use, production method therefor and use of same Download PDFInfo
- Publication number
- CN101977589B CN101977589B CN200980109724.7A CN200980109724A CN101977589B CN 101977589 B CN101977589 B CN 101977589B CN 200980109724 A CN200980109724 A CN 200980109724A CN 101977589 B CN101977589 B CN 101977589B
- Authority
- CN
- China
- Prior art keywords
- acid
- gel
- chitosan
- skin
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 62
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000499 gel Substances 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- 230000002421 anti-septic effect Effects 0.000 claims description 15
- 239000000017 hydrogel Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 claims description 10
- 229940093424 polyaminopropyl biguanide Drugs 0.000 claims description 10
- 239000004310 lactic acid Substances 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 239000004227 calcium gluconate Substances 0.000 claims description 6
- 229960004494 calcium gluconate Drugs 0.000 claims description 6
- 235000013927 calcium gluconate Nutrition 0.000 claims description 6
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 6
- 235000015165 citric acid Nutrition 0.000 claims description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 6
- 239000004299 sodium benzoate Substances 0.000 claims description 6
- 235000010234 sodium benzoate Nutrition 0.000 claims description 6
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 claims description 5
- 230000000172 allergic effect Effects 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 4
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 4
- 230000007797 corrosion Effects 0.000 claims description 4
- 238000005260 corrosion Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 208000035874 Excoriation Diseases 0.000 claims description 3
- 206010040844 Skin exfoliation Diseases 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 230000035618 desquamation Effects 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 235000018062 Boswellia Nutrition 0.000 claims description 2
- 241000628997 Flos Species 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 241001057584 Myrrha Species 0.000 claims description 2
- 241000208181 Pelargonium Species 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 208000010744 skin desquamation Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 240000007551 Boswellia serrata Species 0.000 claims 1
- 206010065755 Lip infection Diseases 0.000 claims 1
- 229940119217 chamomile extract Drugs 0.000 claims 1
- 235000020221 chamomile extract Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 abstract description 18
- 229940101267 panthenol Drugs 0.000 abstract description 15
- 235000020957 pantothenol Nutrition 0.000 abstract description 15
- 239000011619 pantothenol Substances 0.000 abstract description 15
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 241000219295 Portulaca Species 0.000 abstract 1
- 206010053615 Thermal burn Diseases 0.000 abstract 1
- 230000001914 calming effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000887 hydrating effect Effects 0.000 abstract 1
- 238000013532 laser treatment Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 229920002101 Chitin Polymers 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 9
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000035876 healing Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229920005615 natural polymer Polymers 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 239000005060 rubber Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 125000003047 N-acetyl group Chemical group 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 241000717739 Boswellia sacra Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 150000002337 glycosamines Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012744 reinforcing agent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NIIRRKXWTSGTNQ-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O.CCCCCCC(O)C(O)=O NIIRRKXWTSGTNQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001608538 Boswellia Species 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FZHXIRIBWMQPQF-SLPGGIOYSA-N aldehydo-D-glucosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FZHXIRIBWMQPQF-SLPGGIOYSA-N 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 230000007799 dermal corrosion Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000002320 enamel (paints) Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- -1 glycolic Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920005690 natural copolymer Polymers 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000002669 organ and tissue protective effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 238000010248 power generation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 231100000108 skin corrosion Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to pharmaceutical compositions designed to leave a protective film on the skin, comprising chitosan and agents conferring curative, calming and hydrating properties on irritated skin. The gel is characterised in that it includes between 2 and 8 % chitosan and pre-defined proportions of other components such as between 0.1 and 90 % Portulaca and between 0.1 and 45 % Panthenol, which confer improved therapeutic characteristics on the product, and other components which provide the gel with particular characteristics and render same suitably stable over a prolonged period of time. Said gel is applied externally and is suitable for use on irritated skin, superficial burns, dermabrasions, post-dermabrasion, post-laser treatment and on eroded skin in general.
Description
Invention is described
The present invention relates to the gel based on chitosan, and relate more specifically to the gel that the excipient preparation of protectiveness thin film is provided after application on skin.
The present invention relates to be characterized as and mix chitosan as the topical application gel of main component.
Chitosan, from natural origin, is therefore biocompatible.It also demonstrates the intrinsic antimicrobial property of its internal characteristics (antifungal and bactericide).It is corresponding to the deacetylated straight-chain polysaccharide of N-acetyl group-GLUCOSAMINE of the deacetylated commercial acquisition of chitin.
Chitosan absorbs for the heavy metal of water and Industry Waste logistics (industrial waste flow), and for developing cosmetic preparation.In addition, the chitin of partial acetylation and chitosan derivatives have been the themes of finding the important research of therapeutant or implantable material.The biocompatibility of the material that comprises chitosan is evaluated specially on blood, wound and bone.
Chitosan (Cohya Y.Cois (1993) J.Microencapsulation, 10 (1): 1-9) in the drug delivery system by gel, have been studied.
In order to carry out the present invention, use many mixture to obtain solution, this solution provides the gel preparation of the percentage ratio of chitosan between 2% to 8%, be associated with other components that suitable treatment characteristic is provided to product, and be applied to after allergic skin, scorch, skin abrasion, desquamation, after laser and cover substantially corrosivity skin.
Chitosan (poly--β-Isosorbide-5-Nitrae-GLUCOSAMINE) is the natural polysaccharide derivant that is called chitin (poly--β-Isosorbide-5-Nitrae-D-acetylglucosamine), and described chitin is mainly found in shell-fish ectoskeleton.
By adding some materials (chitosan, Herba Portulacae, alpha-hydroxy acid, panthenol and harmless antiseptic), can improve and improve the character of biodegradable polymer.By using the biological degradability of acceptance and the composition of therapeutic properties with general at burn in the skin of damaged or corrosion, the support gel of the present invention of generation is fully biodegradable, has the character of improvement, and they can low cost obtain.
The main Types in water by chitosan is dissolved in good solubility is the organic acid soln of 'alpha '-hydroxy acids, obtain chitosan gel rubber, described alpha-hydroxy acid such as glycolic, lactic acid, α hydroxyacetic acid, α Hydroxycaprylic acid (alpha hydroxyoctanoic acid), α hydroxyl caprylic acid (alphahydroxycaprilic acid), malic acid, citric acid and tartaric acid.By using 25,000g/mol to 1, the number molecular weight scope between 250,000g/mol the chitosan having higher than 80% de-acetyl level obtain hydrogel.
In order to improve the character of hydrogel, add another natural materials of panthenol and Herba Portulacae and similar characteristic, the ratio of every kind changes between 0.1% to 45%.
Unexpectedly obtained the stable article of pH 5.0 to 5.9, its chitosan with the percentage ratio between 0.2% to 10% is prepared as unique viscosifier (viscosifier), by adding at least two kinds of antiseptic, also comprise Herba Portulacae and panthenol and another natural component, described another natural component provides the correlated characteristic of the type damage for the treatment of burn or skin corrosion, causes rapid regeneration and the healing of damaged tissues.
In a series of additional photos, pay close attention to the effect of hydrogel to damaged skin.Caption is as follows:
Fig. 1 shows the lower limb of the people with scorch
Leg area after Fig. 2 and 3 display application hydrogels, it has one deck tissue protective and reproducibility product.
Fig. 4 shows the region of product application after three days, has the treatment benefit that obvious damaged tissues recovers to have proved hydrogel.
Method prepared by hydrogel is as follows:
In thering is the rustless steel container of distilled water, add the organic acid of dilution, by its homogenize, and during preparing hydrogel, make pH remain between 4.0 to 4.5; Then, all chitosans that comprise in formula are slowly added until dissolve completely under continuous stirring.
Then, add polyaminopropyl biguanide, gluconic acid lactone, sodium benzoate and calcium gluconate antiseptic, or the mixture of other antiseptic of comprising of this patent, then add Herba Portulacae or another natural extract, then add panthenol.
Finally, between pH regulator to 5.0 and 5.9, use organic acid soln or 2% sodium hydroxide solution of the dilution between 1% and 2% for this reason.
Then goods are stored in hermetic container, until subpackage (fractioning).
In this patent, the compositions of report is exemplary, but does not limit the scope of the invention and protect.
Embodiment 1
Chitosan powder 3.50g
Polyaminopropyl biguanide 1.50g
Herba portulacae extract 4.00g
Panthenol 4.00g
The appropriate pH 5.5 of citric acid 1%w/v
Distilled water, appropriate 100g
Embodiment 2
Chitosan powder 4.00g
Polyaminopropyl biguanide 1.5g
Herba portulacae extract 6.0g
Panthenol 4.0g
The appropriate pH 5.5 of citric acid 1%p/v
Distilled water, appropriate 100g
Embodiment 3
Chitosan powder 4.00g
Polyaminopropyl biguanide 1.5g
Herba portulacae extract 4.0g
Panthenol 6.0g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
Embodiment 4
Chitosan powder 8.0g
Polyaminopropyl biguanide 1.5g
Herba portulacae extract 4.0g
Panthenol 6.0g
The appropriate pH 5.5 of citric acid 1%p/v
Distilled water, appropriate 100g
Embodiment 5
Chitosan powder 3.50g
Polyaminopropyl biguanide 1.50g
Gluconic acid lactone/sodium benzoate/calcium gluconate 1.50g
Herba portulacae extract 4.00g
Panthenol 4.00g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
Embodiment 6
Chitosan powder 4.0g
Polyaminopropyl biguanide 1.50g
Gluconic acid lactone/sodium benzoate/calcium gluconate 1.50g
Herba portulacae extract 6.00g
Panthenol 4.00g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
Embodiment 7
Chitosan powder 4.0g
Polyaminopropyl biguanide 1.50g
Gluconic acid lactone/sodium benzoate/calcium gluconate 1.50g
Herba portulacae extract 4.00g
Panthenol 6.00g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
Embodiment 8
Chitosan powder 8.0g
Polyaminopropyl biguanide 1.50g
Gluconic acid lactone/sodium benzoate/calcium gluconate 1.50g
Herba portulacae extract 4.00g
Panthenol 6.00g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
The stability of compositions
1st month | 2nd month | 3rd month | |||||||||
Embodiment | Viscosity | pH | Microbiology | Viscosity | pH | Microbiology | Viscosity | pH | Microbiology | ||
1 | 10,000cps | 5.5 | Lower than 100 | 100cps | 5.4 | Higher than 1000 | 100cps | 5.4 | Higher than 1000 | ||
2 | 12,000cps | 5.5 | Lower than 100 | 50cps | 5.5 | Higher than 1000 | 50cps | 5.5 | Higher than 1000 | ||
3 | 12,000cps | 5.5 | Lower than 100 | 200cps | 5.4 | Higher than 1000 | 200cps | 5.2 | Higher than 1000 | ||
4 | 15,000cps | 5.5 | Lower than 100 | 200cps | 5.3 | Higher than 1000 | 200cps | 5.3 | Higher than 1000 | ||
5 | 11,000cps | 5.5 | Lower than 100 | 11,500cps | 55 | Lower than 100 | 11,900cps | 5.5 | Lower than 100 | ||
6 | 14,000cps | 5.5 | Lower than 100 | 14,800cps | 5.4 | Lower than 100 | 14,600cps | 5.4 | Lower than 100 | ||
7 | 15,000cps | 5.5 | Lower than 100 | 15,300cps | 5.4 | Lower than 100 | 15,100cps | 5.5 | Lower than 100 | ||
8 | 18,000cps | 5.5 | Lower than 100 | 18,200cps | 5.5 | Lower than 100 | 18,100cps | 5.5 | Lower than 100 |
The explanation of end product:
Outward appearance, in midium-viscosity gel, suspension without external source granule, yellowish and translucent color.K value is between 5.000cps and 20.000cps.
PH value is between 5.0 to 5.9
Microbiology: pathogen-free domestic and have a liking for warm aerobe≤100UFC/ gram, and fungus and yeast≤100UFC/g;
Table 1 shows the importance that comprises antiseptic in hydrogel blend composition, in embodiment 1 to 4, compositions has less variation, but the most important thing is only to comprise a kind of antiseptic, in embodiment 5 to 8, compositions has less variation, but the most important thing is the mixture that comprises antiseptic in their composition.From the result of table, observe: at the second month of research, notice that significant viscosity changes, observe to produce in preparation 1 to 4 and significantly reduce and significantly microbial contamination, particularly by fungal contamination.This does not occur in comprising the embodiment 5 to 8 of preservative blends.
Under the environmental condition (25 ℃ ± 2 ℃ and 60 ± 5%H) of normal temperature and relative humidity, carry out this measuring.
Need to use the mixture of antiseptic is unusual and beat all (product description) to keep this condition, because expected that a kind of use of antiseptic is enough to keep the stability of product.Only a kind of use of antiseptic will can not predicted the variation of those viscositys of observing.
Prior art
Many gels are disclosed for scorch treatment and allergic skin.
Hydrogel generally has high biocompatibility, and they are for medical science transplanting, treatment of wounds and are also used as the good candidate that medicine is controlled release and sustained release array.
Tomihata has studied in body and the degraded (K.Tomihata and Y.Ikada, Biomaterials 18,567-575 (1997)) of external chitin and chitosan.According to the hydrolysis rate of lysozyme, measure external degradation, and in Animal Experimental Study, measure vivo degradation.
Result shows that 100% acetylizad chitin and 69% deacetylated chitosan are degraded rapidly.
Disclose many hydrogels and be used for the treatment of wound and burn, the gel being formed by chitosan, G & W forms protectiveness film when being applied to skin, uses the chitosan concentration of 1-4%, preferably 1% concentration.This gel is proposed as pharmaceutical carrier substantially, such as silver sulfadiazine vasodilation, analgesic and anti-inflammatory agent (US 4,659,700).
Other hydrogels can have undissolved feature, because added the excipient (US 5,620,706) with opposite charges.
Hydrogel comprises polycation or the polynary medicine of similar chitosan, such as natural polycation, its with such as the polyanion complexation of xanthan gum.It is conventionally by sealing for controlled release preparation.
Other disclosed hydrogels are from the interaction of chitosan and polyvidon, their (N-vinyl lactam)-chitosan gel rubbers that is poly-, and absorb more in particular gel, and they can adhere to skin, have pliability, and are applicable to moulding.According to other preparation compositions, this gel can be used as wound, burn, beauty mask coating (cosmetic mask coating) and beauty treatment porcelain glaze coating (cosmetic enamel coating) (ES 211782).
Also disclose also other gels based on chitosan and polyvidon, comprised the chitosan of the neutralization and do not have with plasticizer and the mixture of poly-(n-vinyl lactam).Gel can form in wound or dressing packing, and wherein hydrocolloid can absorb exudate, and loss structure not.It also can be used as the pharmaceutical carrier (W02002/02079) of transdermal device.
For other of the part of prior art chitosan between chitosan-based in 0.1% to 0.5%, polynary alkoxide or sugar between 1% to 2%.The salt of mentioning can be glycerol binary monophosphate (glycerol dibasic monophosphate).
This gel can original position form, and parenteral administration, or can also be as the vehicle (ES 2205471) of using non-drug products.
Other chitosan preparations of describing in gel comprise uses chitosan or its salt, PAPE or sugar phosphate, plasticizer and therapeutic agent.It refers to aqueous solution or water slurry, and wherein plasticizer is triethyl citrate.The chitosan using has 40% or higher deacetylation.
This gel is for passing through the drug delivery across mucosa (mucose), and application is nose application, vaginal application, rectum application, oral application or ophthalmic applications (WO 2005/079749).
The gel that is used for the treatment of burn has also been described, the collagen protein of this gel based on partial hydrolysis, and add galactose, pectin and hydroxyethyl-cellulose monomer, this gel is used for the treatment of first-degree burn and second degree burns (US2003/000830).
For other disclosed gels of the part of prior art are formed by hydrophilic poly-(aldehyde) and the mixture of polymer, the choosing of described polymer is the following group forming freely: poly-(amide), poly-(amine), poly-(alcohol) and their mixture, comprise natural polymer, chitosan and belong to the mixture (WO00/47149) of poly-(amine).
This gel is substantially as active agent carrier or mixture, also as wound gauze.
The gel that is used for the treatment of burn is also disclosed, the polymer of this gel based on not comprising chitosan, by polyvinyl alcohol, agar and one or more natural polymers, prepared described natural polymer such as gelatin, chondrus ocellatus Holmes polysaccharide (carragenan), sodium alginate, carboxymethyl cellulose, guar gum and Radix Acaciae senegalis (WO01/30407).
Also disclose other hydrogels based on chitosan, it is preferably as antiseptic.This is the chitosan iodide (US2002/0119205) that by concentration range prepared by the chitosan between 5% to 25%, propylene glycol, ethylene glycol etc. and the elemental iodine of concentration range between 0.05% and 1%.
The skin of human body is on average a little more than 1.9m
2, in many functions of skin, except as disease barrier and allow to remove refuse and bodily protection, skin is extremely important for thermoregulation.When skin is destroyed or damages by any wound, traumatic skin impact not only causes somatic damage, also destroys the physiologic function of interior tissue.
Skin treating can or be also referred to as porosu solid through irrigating solution and coating sponge.
Be similar to chitosan, chitin analyzed as being with skin in the glycosaminoglycan found feature class seemingly, because chitin repetitive n-acetylglucosamine is present in hyaluronic acid, and be responsible for being formed on the protein fibre network of combination during wound healing.Therefore, chitin compound is also considered as promoter and the wound healing process reinforcing agent of skin rapid regeneration by several researcheres, because the healing rate that chitin shows makes it be used as the composition product of the medicine being applied on wound.
Because compare with chitin n-acetylglucosamine, the effect that the healing of the glycosamine residue in chitosan strengthens ability is lower, so chitosan is after the chitin as agglutination reinforcing agent.
Chitin is distributed widely in occurring in nature, is distributed in regnum animale and plant kingdom.In fact, it is the natural polymer more than second, only have cellulose to surpass it, so it is Renewable resource.This polymer comprises the amino sugar by β (1 4) glycosidic bond bonding, wherein forms N-acetyl group-2-amino-2-deoxy-D-Glucose unit straight chain, and some in them are by deacetylation.Natural chitin is proved to be the degree of acetylation with 66%, and every three unit just have one to be deacetylated.
Chitosan is the linear polysaccharide by chitin deacetylated acquisition on a large scale; and comprise construction unit N-acetyl group-GLUCOSAMINE and the GLUCOSAMINE along chain random distribution (Bemoullian distribution) of two types, between them, by β (1 4) type glycosidic bond, connect.Deacetylated chitosan structure is presented in Fig. 1 .2 completely.Yet it is very difficult making the completely de-acetyl of chitin, and what be commonly referred to chitosan is the chitin family having generally higher than 45% different degree of deacetylation.It is it and chitinous common acceptable standard of difference that chitosan is dissolved in ability in the aqueous acid of dilution.
Fig. 1 .2
All biomaterials for clinical setting should have excellent surface nature, because when this material implants, they directly contact living tissue.Initial somatic reaction to biomaterial depends on these character.
Chitosan can be used as artificial skin with healing acceleration, and for ulcer healing, or as the vehicle of drug release.The chitosan of positively charged and their biocompatibility provide effective Growth of Cells support.
Except providing to gel preparation the natural copolymer chitosan of special nature, also comprise other compositions, make product on allergic skin, burn and superficial cut, there is better effect.
Be a panthenol, also referred to as B5 provitamin, D-panthenol is converted to vitamin B5 in vivo, a kind of normal skin and hair composition, and its topical application is accelerated cell regeneration, and is powerful humidizer.
When the pantothenylol of topical application is converted into the D-VB5 (or simply pantothenic acid) of healthy skin, act on mitochondrial biochemical power generation circulation, and for lipid, protein synthesis and lipid-protein, to be connected with chain between saccharide be essential.
When enough d-pantothenic acid does not exist, produce known cutaneous manifestations, such as keratinization, depigmentation with come off.
Panthenol absorbs fast by skin, becomes pantothenic acid.
Cell regeneration is accelerated by the topical application of d-panthenol, because it has height skin penetrating power and special humidizer ability.It also contributes to the skin that humidification is aging, and be applied to ideally mild skin and stimulate (Lawrence Sweetman, Encyclopedia of Dietary Supplements (food additives encyclopedia), Pantothenic Acid (pantothenic acid), in February, 2005).
The compatible material of other biological can add in this chitosan gel rubber, and this material demonstrates advantage during local application in corrosion skin treating.One of this class material is Herba Portulacae, and it is available from the plant extract that is called Herba Portulacae.This extract has good irritation and antiinflammatory action when local use.Herba portulacae extract has been successfully used to several dermatopathies, such as eczema and abscess (the people .Las plantas silvestres.Los remedies hist ó ricosdermatol ó gicos.Med.Cutan.Iber.Lat.2003 such as PedroS á nchex Sambucety, 31 (5): 337-346).Having other native compounds of curing character and being used because of their skin treating character is extract and the linoleic acid from Olibanum wood (Boswellia sacra), Herba stellariae mediae, Big Semen Plantaginis, Flos Inulae, Boswellia carterii (Boswella carterii), Myrrha, Chamaemelum nobile (L.) A L L, Pelargonium gravelens.
Claims (10)
1. the hydrophilic stable gel based on topical application polymer, is characterized in that:
A) comprise chitosan,
B) chitosan is by adding dissolution with solvents,
C) comprise one or more materials that increase organized renewing ability,
D) comprise at least two kinds of antiseptic harmless to skin, described at least two kinds to the harmless antiseptic of skin, the mixture with polyaminopropyl biguanide, gluconic acid lactone, sodium benzoate and calcium gluconate exists, and the concentration of every kind of antiseptic changes between 0.1% to 30%.
2. gel according to claim 1, is characterized in that chitosan has 25,000g/mol to 1, and the molecular weight between 250,000g/mol, it is main hydrogel component, and exists with the ratio changing between 2% to 8%.
3. according to the gel described in any one in claim 1 to 2, it is characterized in that described solvent is from the organic acid that is selected from the dilution of following alpha-hydroxy acid family: glycolic, lactic acid, α hydroxyacetic acid, α Hydroxycaprylic acid, α hydroxyl caprylic acid, malic acid, citric acid and tartaric acid.
4. according to the gel described in any one in claim 1 to 2, it is characterized in that one or more materials of described increase organized renewing ability are selected from Herba portulacae extract, Herba stellariae mediae extract, Big Semen Plantaginis extract, Flos Inulae extract, Boswellia carterii extract, Myrrha extract, chamomile extract, Pelargonium gravelens extract and linoleic acid.
5. gel according to claim 4, it is characterized in that described increase organized renewing ability one or more materials each with percentage change between 0.1% to 45%, be included.
6. for obtaining a method for the gel of the topical application described in claim 1 to 5 any one, it is characterized in that thering are following steps:
A) by the 1-2%w/v weak organic acid solution that contains the chitosan between 2% to 8%w/w, prepare chitosan solution,
B) with the ratio changing between 0.1% to 30%, every kind of antiseptic is joined in the solution obtaining in (a),
C) then, after described this solution is even, under continuous stirring, with the ratio changing, add one or more materials that increase organized renewing ability between 0.1% to 45%,
D) finally use dilution organic acid soln between 2% sodium hydroxide solution or 1% to 2% by pH regulator to 5.0 between 5.9.
7. method according to claim 6, is characterized in that using being selected from following alpha-hydroxy acid as organic acid: glycolic, lactic acid, α hydroxyacetic acid, α Hydroxycaprylic acid, α hydroxyl caprylic acid, malic acid, citric acid and tartaric acid.
8. the purposes in the medicine for the preparation for the treatment of allergic skin and burn according to the gel described in any one in claim 1 to 5, is characterized in that described medicine is that topical application by thin layer is used for the treatment of allergic skin and burn.
9. the purposes in the medicine of the treatment after for the preparation for the treatment of skin abrasion, desquamation and after laser according to the gel described in any one in claim 1 to 5, it is characterized in that described medicine is by infected lip-deep applied in very thin layers, for the treatment after skin abrasion, desquamation and after laser.
10. the purposes in the medicine of the skin for the preparation for the treatment of corrosion according to the gel described in any one in claim 1 to 5, is characterized in that described medicine is by the application of the lip-deep layer being treated, and is used for the treatment of the skin of corrosion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL200800156A CL2008000156A1 (en) | 2008-01-18 | 2008-01-18 | STABLE HYDROPHYLE GEL BASED ON A POLYMER FOR TOPICAL APPLICATION BECAUSE IT INCLUDES DISSOLVED CHITOSANE IN A SOLVENT; PROCESS TO OBTAIN THE GEL FOR TOPICAL USE BEFORE MENTIONED; USE OF THE GEL. |
PCT/IB2009/050228 WO2009090624A2 (en) | 2008-01-18 | 2009-01-21 | Chitosan gel for dermatological use, production method therefor and use of same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101977589A CN101977589A (en) | 2011-02-16 |
CN101977589B true CN101977589B (en) | 2014-12-10 |
Family
ID=40261146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980109724.7A Expired - Fee Related CN101977589B (en) | 2008-01-18 | 2009-01-21 | Chitosan gel for dermatological use, production method therefor and use of same |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100316739A1 (en) |
EP (1) | EP2452673B1 (en) |
JP (1) | JP5615717B2 (en) |
CN (1) | CN101977589B (en) |
AR (1) | AR071334A1 (en) |
BR (1) | BRPI0906932A2 (en) |
CA (1) | CA2712527C (en) |
CL (1) | CL2008000156A1 (en) |
CO (1) | CO6331421A2 (en) |
EC (1) | ECSP10010352A (en) |
ES (1) | ES2361459B1 (en) |
MX (1) | MX2010007902A (en) |
PE (1) | PE20091363A1 (en) |
WO (1) | WO2009090624A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105055582A (en) * | 2015-08-18 | 2015-11-18 | 云南同方科技有限公司 | Formula essential oil for slight skin burns and scalds |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012177825A1 (en) * | 2011-06-21 | 2012-12-27 | Bvw Holding Ag | Medical device comprising boswellic acid |
WO2013112381A2 (en) * | 2012-01-24 | 2013-08-01 | Bvw Holding Ag | New class of anti-adhesion hydrogels with healing aspects |
RU2526183C1 (en) * | 2013-02-28 | 2014-08-20 | Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства (ФГУП НПЦ "Фармзащита" ФМБА России) | Haemostatic anti-burn wound-healing composition |
EP3119404B1 (en) * | 2014-03-17 | 2019-07-24 | Global Bioprotect IP Pty Ltd | Antimicrobial sanitizer compositions and their use |
CN103919689A (en) * | 2014-03-20 | 2014-07-16 | 金红叶纸业集团有限公司 | Wet tissue emulsion, wet tissue and preparation method of wet tissue |
GB201501333D0 (en) | 2015-01-27 | 2015-03-11 | Medtrade Products Ltd | Composition for a wound dressing |
GB201501330D0 (en) * | 2015-01-27 | 2015-03-11 | Medtrade Products Ltd | Composition for a wound dressing |
EA026104B1 (en) * | 2015-04-02 | 2017-03-31 | Общество С Ограниченной Ответственностью "Тектум" | Haemostatic and wound healing medicine |
US10751444B2 (en) | 2015-08-07 | 2020-08-25 | Victor Matthew Phillips | Flowable hemostatic gel composition and its methods of use |
US10660945B2 (en) | 2015-08-07 | 2020-05-26 | Victor Matthew Phillips | Flowable hemostatic gel composition and its methods of use |
WO2018005145A1 (en) * | 2016-06-28 | 2018-01-04 | Victor Matthew Phillips | Flowable hemostatic gel composition and its methods of use |
US11058712B2 (en) | 2017-07-19 | 2021-07-13 | Universidade Da Beira Interior | Film for topical application in the treatment of skin lesions and method of obtaining and applying same |
CN108514546B (en) * | 2018-05-14 | 2020-09-29 | 山东师范大学 | Chitosan hydrogel preparation of dihydromyricetin and preparation method thereof |
CN109731021A (en) * | 2019-03-20 | 2019-05-10 | 武汉市思泰利医疗器械发展有限公司 | It is a kind of for treat repair stoma skin aquagel and preparation method thereof |
US20220211606A1 (en) * | 2019-04-08 | 2022-07-07 | Medoderm Gmbh | Liquid composition for influencing the microbiota on a subject's skin comprising chitosan |
EP3996914A4 (en) * | 2019-07-11 | 2023-08-02 | Stenco, LLC | Biodegradable material |
CN111920742A (en) * | 2020-09-18 | 2020-11-13 | 微著生物科技(东营)有限责任公司 | Chitosan multi-effect repair mask and preparation method thereof |
EP4228595A1 (en) * | 2020-10-14 | 2023-08-23 | Medoderm GmbH | Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease |
DE102021109834A1 (en) * | 2021-04-19 | 2022-10-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein | Composition for disinfection and cosmetic use |
WO2023233299A1 (en) | 2022-05-31 | 2023-12-07 | Instituto Politécnico Da Guarda | Wound dressing comprising a ph sensor composition and method of producing the same |
WO2024136811A1 (en) * | 2022-12-20 | 2024-06-27 | Istanbul Medipol Universitesi | Wound healing gel formulation comprising melaleuca viridiflora l. and boswellia carterii l. |
US11845859B1 (en) | 2023-03-28 | 2023-12-19 | King Faisal University | Biopolymer derived from algae |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659700A (en) | 1984-03-02 | 1987-04-21 | Johnson & Johnson Products, Inc. | Chitosan-glycerol-water gel |
US5013769A (en) * | 1988-08-22 | 1991-05-07 | Medipro Sciences Limited | Method of making a hydrogel-forming wound dressing or skin coating material |
US5142010A (en) * | 1990-05-10 | 1992-08-25 | H. B. Fuller Licensing & Financing Inc. | Polymeric biocidal agents |
AU9115791A (en) * | 1990-11-30 | 1992-06-25 | Baker Cummins Dermatologicals, Inc. | Skin protective compositions and method of inhibiting skin irritation |
US5420197A (en) | 1994-01-13 | 1995-05-30 | Hydromer, Inc. | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
US5620706A (en) | 1995-04-10 | 1997-04-15 | Universite De Sherbrooke | Polyionic insoluble hydrogels comprising xanthan and chitosan |
SE507028C2 (en) * | 1996-08-06 | 1998-03-16 | Medicarb Ab | New medical use |
DE19719856A1 (en) * | 1997-05-12 | 1998-11-19 | Henkel Kgaa | Skin care products |
CA2212300A1 (en) | 1997-08-04 | 1999-02-04 | Abdellatif Chenite | In vitro or in vivo gelfying chitosan and therapeutic uses thereof |
DE19826503A1 (en) * | 1998-06-13 | 1999-12-16 | Beiersdorf Ag | Cosmetic and dermatological preparations containing chitosan and phospholipids |
US6121375A (en) | 1999-02-11 | 2000-09-19 | Hydromer, Inc. | Gels formed by the interaction of poly(aldehyde) with various substances |
EP1223986A2 (en) * | 1999-06-11 | 2002-07-24 | Shearwater Corporation | Hydrogels derived from chitosan and poly(ethylene glycol) |
WO2001030407A1 (en) | 1999-10-27 | 2001-05-03 | Department Of Atomic Energy | A process for manufacture of hydrogels for burn and injury treatment |
DE10010199A1 (en) * | 2000-03-02 | 2001-09-06 | Beiersdorf Ag | Aqueous-alcoholic preparations containing chitosan |
US6379702B1 (en) | 2000-07-05 | 2002-04-30 | Hydromer, Inc. | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
KR100391781B1 (en) * | 2000-12-14 | 2003-07-16 | 주식회사 제닉 | Soft gel comprising chitosan and gelatin |
US6521243B2 (en) | 2000-12-22 | 2003-02-18 | Pharma C And D, Limited | Ionic chitosan -iodine complexes: antiseptic hydrogels and wound healing promoters |
US20030000830A1 (en) | 2001-02-23 | 2003-01-02 | Techquip International, Inc. | Stacked panel processing apparatus and methods |
JP3947391B2 (en) * | 2001-11-28 | 2007-07-18 | 独立行政法人 日本原子力研究開発機構 | Method for producing chitin derivative and / or chitosan derivative having bridge structure |
FR2836044A1 (en) * | 2002-02-15 | 2003-08-22 | Octaris | COMPOSITION FOR REPAIR AND SKIN HEALING EXCLUSIVELY INCLUDING A TRUE PHYSICAL HYDROGEL OF CHITOSAN |
EP2340856B2 (en) * | 2003-05-24 | 2017-11-15 | La Prairie Group AG | Cosmetic or dermatologic formulation comprising a nutrient medium phase |
KR100506543B1 (en) * | 2003-08-14 | 2005-08-05 | 주식회사 제닉 | Temperature Sensitive State-Changing Hydrogel Composition and Method for their Preparation |
JP2006045181A (en) * | 2003-11-18 | 2006-02-16 | Sekisui Chem Co Ltd | External composition for skin |
GB0403938D0 (en) | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
US20050196450A1 (en) * | 2004-03-04 | 2005-09-08 | Elka Touitou | Method and composition for burned skin |
KR100676937B1 (en) * | 2005-06-01 | 2007-02-02 | 주식회사 제닉 | Water soluble film for skin care and wound repair and method for their preparation |
US20070048358A1 (en) * | 2005-08-31 | 2007-03-01 | Schorr Phillip A | Antimicrobial substrates |
US20070237811A1 (en) * | 2006-04-10 | 2007-10-11 | Scherr George H | Chitosan wound dressing |
CN101057953A (en) * | 2006-04-21 | 2007-10-24 | 陈祖辉 | Multi-target cooperative control preparation for treating virus infectious disease |
-
2008
- 2008-01-18 CL CL200800156A patent/CL2008000156A1/en unknown
-
2009
- 2009-01-16 AR ARP090100136A patent/AR071334A1/en not_active Application Discontinuation
- 2009-01-16 PE PE2009000057A patent/PE20091363A1/en not_active Application Discontinuation
- 2009-01-21 BR BRPI0906932-1A patent/BRPI0906932A2/en not_active IP Right Cessation
- 2009-01-21 MX MX2010007902A patent/MX2010007902A/en active IP Right Grant
- 2009-01-21 CN CN200980109724.7A patent/CN101977589B/en not_active Expired - Fee Related
- 2009-01-21 ES ES201050012A patent/ES2361459B1/en not_active Expired - Fee Related
- 2009-01-21 CA CA2712527A patent/CA2712527C/en not_active Expired - Fee Related
- 2009-01-21 EP EP09702300.6A patent/EP2452673B1/en not_active Not-in-force
- 2009-01-21 JP JP2010542731A patent/JP5615717B2/en not_active Expired - Fee Related
- 2009-01-21 US US12/863,551 patent/US20100316739A1/en not_active Abandoned
- 2009-01-21 WO PCT/IB2009/050228 patent/WO2009090624A2/en active Application Filing
-
2010
- 2010-07-16 EC EC2010010352A patent/ECSP10010352A/en unknown
- 2010-08-09 CO CO10097192A patent/CO6331421A2/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105055582A (en) * | 2015-08-18 | 2015-11-18 | 云南同方科技有限公司 | Formula essential oil for slight skin burns and scalds |
CN105055582B (en) * | 2015-08-18 | 2018-09-04 | 云南同方科技有限公司 | A kind of formula essential oil for the slight burn and scald of skin |
Also Published As
Publication number | Publication date |
---|---|
JP5615717B2 (en) | 2014-10-29 |
US20100316739A1 (en) | 2010-12-16 |
WO2009090624A2 (en) | 2009-07-23 |
EP2452673A4 (en) | 2013-04-03 |
EP2452673B1 (en) | 2017-04-26 |
BRPI0906932A2 (en) | 2015-07-28 |
CO6331421A2 (en) | 2011-10-20 |
WO2009090624A3 (en) | 2009-09-11 |
EP2452673A2 (en) | 2012-05-16 |
AR071334A1 (en) | 2010-06-16 |
JP2012515710A (en) | 2012-07-12 |
CA2712527C (en) | 2017-02-28 |
MX2010007902A (en) | 2010-11-25 |
ES2361459A8 (en) | 2011-07-21 |
CL2008000156A1 (en) | 2008-08-01 |
ES2361459A1 (en) | 2011-06-17 |
CN101977589A (en) | 2011-02-16 |
ES2361459B1 (en) | 2012-04-24 |
PE20091363A1 (en) | 2009-10-15 |
ECSP10010352A (en) | 2010-11-30 |
CA2712527A1 (en) | 2009-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101977589B (en) | Chitosan gel for dermatological use, production method therefor and use of same | |
Pires et al. | Polymer-based biomaterials for pharmaceutical and biomedical applications: A focus on topical drug administration | |
Ullah et al. | Applications of bacterial cellulose in food, cosmetics and drug delivery | |
US11191274B2 (en) | Biofilm penetrating compositions and methods | |
AU639163B2 (en) | Methyl pyrrolidinone chitosan, production process and uses thereof | |
EP3060266B1 (en) | Chitosan paste wound dressing | |
KR102659079B1 (en) | Chitosan-containing preparations and methods for their preparation and use | |
WO2014147638A1 (en) | A multifunctional natural wound healing matrix | |
KR20060048401A (en) | Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound | |
Kumar et al. | Recent advances in the use of algal polysaccharides for skin wound healing | |
Kumar et al. | Marine-derived polysaccharides and their therapeutic potential in wound healing application-A review | |
CN108158995A (en) | A kind of gynaecology's anti-bacteria foaming agent containing chitosan and preparation method thereof | |
Gokarneshan | Application of natural polymers and herbal extracts in wound management | |
Kolipaka et al. | Stimuli-responsive polysaccharide-based smart hydrogels for diabetic wound healing: Design aspects, preparation methods and regulatory perspectives | |
Priya et al. | Exploring polysaccharide-based bio-adhesive topical film as a potential platform for wound dressing application: A review | |
Joshi et al. | Marine polysaccharides: biomedical and tissue engineering applications | |
Zubair et al. | Emerging trends and challenges in polysaccharide derived materials for wound care applications: A review | |
JP2010533154A (en) | Chitosan carboxyalkylamide hydrogel, its preparation and its cosmetic and dermatological use | |
Şenel et al. | Application of chitosan based scaffolds for drug delivery and tissue engineering in dentistry | |
EP3656404A1 (en) | Film for topical use for treating skin lesions and method for producing and applying same | |
KR102503193B1 (en) | Hydrogel comprising Mushroom-derived Chitosan or derivatives thereof and Manufacturing Method thereof | |
US20190247421A1 (en) | Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan | |
WO2015013821A1 (en) | Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan | |
Adetunji et al. | Nanochitosan derived from marine annelids | |
Quadir et al. | Bioresorbable polymers for wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141210 Termination date: 20190121 |
|
CF01 | Termination of patent right due to non-payment of annual fee |